From: "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer
Lines of Endocrine therapy
3 rd line
4 th line
N
6
2
N with CB (%)
3 (50.0)
1 (50.0)
Median DOR with CB (months)
15.0 (13–32)
9.0
N still receiving treatment
0